| Target Price | $17.34 | 
| Price | $7.25 | 
| Potential | 
      
            
    
      
    
  139.17%
     register free of charge | 
| Number of Estimates | 14 | 
| 14 Analysts have issued a price target BioCryst Pharmaceuticals, Inc. 2026 .
        The average BioCryst Pharmaceuticals, Inc. target price is $17.34.
        This is 
       
    
      
    
  139.17%
     register free of charge 
                $31.50 
    
      
    
  334.48%
     register free of charge 
                $11.11 
    
      
    
  53.24%
     register free of charge | |
| A rating was issued by 17 analysts: 15 Analysts recommend BioCryst Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the BioCryst Pharmaceuticals, Inc. stock has an average upside potential 2026 of 
       
    
      
    
  139.17%
     register free of charge | 
| Dec '24 | 2025 Estimates | |
|---|---|---|
| Revenue Million $ | 450.71 | 637.31 | 
| 36.00% | 41.40% | |
| EBITDA Margin | -0.29% | 14.80% | 
| 99.05% | 5,231.16% | |
| Net Margin | -19.72% | 2.88% | 
| 71.15% | 114.60% | 
14 Analysts have issued a sales forecast BioCryst Pharmaceuticals, Inc. 2025 . The average BioCryst Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an BioCryst Pharmaceuticals, Inc. EBITDA forecast 2025. The average BioCryst Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 BioCryst Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average BioCryst Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 | 2025 Estimates | |
|---|---|---|
| Earnings Per Share $ | -0.43 | 0.09 | 
| 63.56% | 120.93% | |
| P/E | 82.78 | |
| EV/Sales | 3.13 | 
15 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast for earnings per share. The average BioCryst Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
BioCryst Pharmaceuticals, Inc....
| Analyst | Rating | Action | Date | 
|---|---|---|---|
| JMP Securities | Locked ➜ Locked | Locked | Oct 15 2025 | 
| TD Cowen | Locked ➜ Locked | Locked | Oct 15 2025 | 
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Oct 15 2025 | 
| Needham | Locked ➜ Locked | Locked | Oct 15 2025 | 
| Needham | Locked ➜ Locked | Locked | Aug 04 2025 | 
| B of A Securities | Locked ➜ Locked | Locked | Jul 01 2025 | 
| RBC Capital | Locked ➜ Locked | Locked | Jun 30 2025 | 
| Analyst Rating | Date | 
|---|---|
| Locked 
            JMP Securities:
             Locked ➜ Locked | Oct 15 2025 | 
| Locked 
            TD Cowen:
             Locked ➜ Locked | Oct 15 2025 | 
| Locked 
            Cantor Fitzgerald:
             Locked ➜ Locked | Oct 15 2025 | 
| Locked 
            Needham:
             Locked ➜ Locked | Oct 15 2025 | 
| Locked 
            Needham:
             Locked ➜ Locked | Aug 04 2025 | 
| Locked 
            B of A Securities:
             Locked ➜ Locked | Jul 01 2025 | 
| Locked 
            RBC Capital:
             Locked ➜ Locked | Jun 30 2025 | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


